SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Ghrelin-based interventions in preclinical models of Parkinson's disease: a systematic review.

Brain Res · 2026-02-03

DOI: 10.1016/j.brainres.2026.150187PMID: 41643910

Check source for accessSystematic Review; Review; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Ghrelin plays a crucial role in metabolism and gastrointestinal function. In the central nervous system, ghrelin modulates both hedonic and homeostatic control of eating behavior. Ghrelin promotes neuron survival by reducing apoptosis, inflammation, and oxidative stress, making it a potential therapeutic agent for neurodegenerative diseases. Parkinson's Disease (PD) is a neurodegenerative disease characterized by motor and non-motor symptoms. The motor impairments result primarily from the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. Individuals with PD exhibit reduced levels of fasting and postprandial plasma ghrelin, and its receptors (GHSR) are expressed in the substantia nigra. Thus, this review aimed to evaluate the effects of ghrelin or GHSR agonists administration in experimental models of PD. A systematic search was conducted across PubMed, Scopus, Web of Science, and Embase. The 12 included studies involved PD models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), as well as A53T transgenic mice. Interventions were performed with acylated and/or des-acylated ghrelin, in addition to the GHSR agonist HM01. Intervention with ghrelin was able to reduce dopaminergic neurodegeneration and improve motor function, while also positively impacting metabolic and gastrointestinal functions, expanding its relevance to non-motor consequences of PD. Considering that most results were obtained using acute toxin-induced models and only male animals, further studies using progressive PD models and evaluating sex differences are needed. Thus, although preclinical evidence supports ghrelin or GHSR agonists as promising agents for treatment, future studies will be essential to inform clinical translation and optimize therapeutic strategies for individuals with PD.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.